Latest 8-K filings

Greenpro Capital Corp. has finalized the sale of its F&A Entities for HK$3.5 million, impacting its financial statements with discontinued operations.

RideNow Group, Inc. has entered into a new term loan credit agreement to refinance existing senior debt and amended three unsecured promissory notes, impacting its capital structure.

Brookfield Asset Management Ltd. announces revisions to its presentation of Fee Revenues and Fee-Related Earnings to provide greater transparency for investors.

Getty Realty Corp. has finalized a $260.9 million sale-leaseback transaction with Refuel Operating Company, LLC, acquiring 41 convenience stores and entering into long-term net leases.

Kodiak Sciences announced that its Phase 3 DAYBREAK study met primary endpoints for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in wet age-related macular degeneration (wAMD).

Lifecore Biomedical, Inc. has entered into a definitive agreement to be acquired by an affiliate of Webster Equity Partners for $6.28 per share in cash, plus contingent value rights.

Core Molding Technologies announced the immediate promotion of Michael J. Gayford to Chief Operating Officer, effective September 28, 2026, tasking him with North American operations and strategic growth initiatives.

Quantum Corporation announced the appointment of James C. Clancy as Chief Operating Officer, effective September 28, 2026, to enhance organizational performance and drive growth.

Park Aerospace Corp. announced a significant increase in the annual base salary for its President and Chief Operating Officer, Mark A. Esquivel, effective September 28, 2026.

H.B. Fuller Company announced the appointment of R. Jeffrey Bailly to its Board of Directors, effective September 23, 2026, bringing extensive experience in medical technologies and corporate transformation.

Silexion Therapeutics announced positive preclinical findings for its lead candidate SIL204, demonstrating its ability to utilize native lipoproteins for cellular delivery and KRAS oncogene knockdown in cancers.

Bitmine Immersion Technologies announces its total crypto, cash, and marketable securities holdings have reached $17.2 billion, with over 6 million ETH tokens, representing 4.9% of the total ETH supply.

Greenland Energy Company announced the successful completion of its 2026 environmental baseline field program at the Jameson Land Project, a key step towards exploration drilling.

Burke & Herbert Financial Services Corp. announced the proposed offering of Fixed-to-Floating Rate Subordinated Notes due 2036 to redeem existing debt and for general corporate purposes.

Silicon Valley Acquisition Corp. has entered into a third amendment to its Business Combination Agreement with EigenQ, Inc., primarily to clarify warrant treatment.

MongoDB announced the immediate resignation of its President and CEO, Chirantan (CJ) Desai, and the appointment of Dev Ittycheria as interim CEO, while reaffirming financial guidance.

Graphic Packaging Holding Company details its corporate governance, stewardship, and sustainability initiatives in its Fall 2026 presentation.

DeFi Development Corp. announced a 10% growth in its SOL and SOL equivalents holdings over six weeks, surpassing 2.5 million SOL, while its preferred stock CHAD offers a 13% annual dividend.

Paramount Skydance Corporation announced its intention to offer approximately $44.4 billion in senior secured notes to finance its acquisition of Warner Bros. Discovery.

Cycurion, Inc. announced projected 2026 revenue of $843,028 from public safety contracts, including a CAD administration role with a potential 10-year value of $3.43 million, while awaiting a Nasdaq delisting appeal decision.

Bold Eagle Acquisition Corp. and REDL Intermediate Holdings, LLC have signed a business combination agreement to take REDLattice, a cyber intelligence solutions provider, public.

TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing significant disease stabilization and extended treatment duration in advanced cancer patients.

Adicet Bio announced positive safety and efficacy data from its Phase 1 study of prula-cel in patients with Systemic Lupus Erythematosus (SLE) with or without Lupus Nephritis (LN), showing high remission rates and a favorable safety profile.

Fate Therapeutics announced a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 clinical trial of FT819 for lupus nephritis.

Volato Group's Alignment Engine subsidiary has signed two take-or-pay orders totaling $1.17 billion for dedicated AI infrastructure with a large AI customer.

4D Molecular Therapeutics has enrolled the first patients in its Phase 3 trial for 4D-150 in diabetic macular edema and released encouraging 2-year data from its SPECTRA trial.

BGC Group, Inc. has announced an update to its financial outlook for the third quarter of 2026, reaffirming previously issued guidance for revenue and pre-tax Adjusted Earnings.

Mirum Pharmaceuticals announced FDA approval for Atebrioz to treat fibrodysplasia ossificans progressiva and positive Phase 3 results for brelovitug in chronic hepatitis delta.

Lakeshore Acquisition III Corp. has extended its deadline to consummate its initial business combination by one month to November 1, 2026, following a third extension payment.

Keros Therapeutics has dosed the first patient in its Phase 2 clinical trial for rinvatercept, a novel therapeutic aimed at treating Duchenne muscular dystrophy (DMD).